TY - THES A1 - Maier-Unverfehrt, Kristin T1 - Der Hygieniker und Medizinhistoriker Georg Sticker (1860-1960) - Leben und Werk T1 - The hygienist and medical historian Georg Sticker (1860-1960) - Life and work N2 - Georg Sticker war Arzt, Hochschullehrer, Hygieniker und Medizinhistoriker. Das Themenspektrum seiner Arbeiten ist sehr umfangreich. Der Schwerpunkt dieser Arbeit liegt auf seinen Hauptforschungsgebieten, der Medizingeschichte und hier vor allem auf der Seuchengeschichte zu Pest, Lepra und Syphilis und der Bedeutung der Geschichte der Epidemien für die Epidemiologie; sowie seinen großen ärztlichen Vorbildern Hippokrates und Paracelsus. Auch über Naturheilkunst und Gesundheit und Erziehung berichtet er mit großem Engagement.Nach seiner Berufung an die Universität Würzburg beendet er seine ärztliche Tätigkeit, gründet hier im Jahr 1921 das Institut für Geschichte der Medizin und widmet sich ganz der Medizingeschichte N2 - Georg Sticker was a doctor, university lecturer, hygienist and medical historian.The range of topics of his work is very extensive. The focus of his work is on his main areas of research, the history of medicine and here especially on the epidemic history of plague, leprosy and syphilis and the significance of the history of epidemics for epidemiology, as well, as his great medical role models Hypocrates and Paracelsus. He also reports with great commitment on naturopathy and health and education. After his appointment to the university of Würzburg, he ended his medical practice and founded the Institute for the History of Medicine here in 1921 and devoted himself entirely to the history of medicine. KW - Sticker, Georg KW - Medizinhistoriker KW - Seuchengeschichte KW - Pest KW - Syphilis KW - Hypokrates und Paracelsus KW - medical historian KW - epidemic history KW - plague KW - syphilis KW - Hypocrates and Paracelsus Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-299135 ER - TY - JOUR T1 - einBlick - Ausgabe 21 - 31. Mai 2011 N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Würzburg KW - Universität KW - University KW - Wuerzburg KW - Wurzburg Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-56909 VL - 21/2011 ER - TY - JOUR T1 - einBlick - Ausgabe 28 - 19. Juli 2016 N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Wurzburg KW - Wuerzburg KW - University KW - Würzburg KW - Universität Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-138397 UR - http://www.presse.uni-wuerzburg.de/einblick/ VL - 28/2016 ER - TY - JOUR T1 - Blick - das Magazin der Julius-Maximilians-Universität Würzburg. Ausgabe 2/1996. Schwerpunktthema: Selektive Reaktionen Metall-aktivierter Moleküle N2 - Inhaltsübersicht zum Schwerpunktthema: - Wozu Metalle nützlich sein können - Ein Beitrag zur "grünen Chemie" - Der gezielte Aufbau "chiraler Achsen" - Selektiver Aufbau von Naturstoffen mit Hilfe von Metallkomplexen - Dynamik des Energietransportes innerhalb von Molekülen - Von Erdöl über Kohlenwasserstoffe zu interessanten Zielmolekülen u.a. KW - Würzburg KW - Universität KW - Zeitschrift KW - Metall KW - Chmie Y1 - 1996 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-44945 VL - 2/1996 ER - TY - JOUR T1 - einBlick - Ausgabe 19 – 16. Mai 2023 T2 - einBlick N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Universität KW - Würzburg KW - University KW - Wuerzburg KW - Wurzburg Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-316519 UR - https://www.uni-wuerzburg.de/aktuelles/einblick/ VL - 19/2023 ER - TY - JOUR A1 - Trübe, Patricia A1 - Hertlein, Tobias A1 - Mrochen, Daniel M. A1 - Schulz, Daniel A1 - Jorde, Ilka A1 - Krause, Bettina A1 - Zeun, Julia A1 - Fischer, Stefan A1 - Wolf, Silver A. A1 - Walther, Birgit A1 - Semmler, Torsten A1 - Bröker, Barbara M. A1 - Ulrich, Rainer G. A1 - Ohlsen, Knut A1 - Holtfreter, Silva T1 - Bringing together what belongs together: Optimizing murine infection models by using mouse-adapted Staphylococcus aureus strains JF - International Journal of Medical Microbiology N2 - Staphylococcus (S.) aureus is a leading cause of bacterial infection world-wide, and currently no vaccine is available for humans. Vaccine development relies heavily on clinically relevant infection models. However, the suitability of mice for S. aureus infection models has often been questioned, because experimental infection of mice with human-adapted S. aureus requires very high infection doses. Moreover, mice were not considered to be natural hosts of S. aureus. The latter has been disproven by our recent findings, showing that both laboratory mice, as well as wild small mammals including mice, voles, and shrews, are naturally colonized with S. aureus. Here, we investigated whether mouse-and vole-derived S. aureus strains show an enhanced virulence in mice as compared to the human-adapted strain Newman. Using a step-wise approach based on the bacterial genotype and in vitro assays for host adaptation, we selected the most promising candidates for murine infection models out of a total of 254 S. aureus isolates from laboratory mice as well as wild rodents and shrews. Four strains representing the clonal complexes (CC) 8, 49, and 88 (n = 2) were selected and compared to the human-adapted S. aureus strain Newman (CC8) in murine pneumonia and bacteremia models. Notably, a bank vole-derived CC49 strain, named DIP, was highly virulent in BALB/c mice in pneumonia and bacteremia models, whereas the other murine and vole strains showed virulence similar to or lower than that of Newman. At one tenth of the standard infection dose DIP induced disease severity, bacterial load and host cytokine and chemokine responses in the murine bacteremia model similar to that of Newman. In the pneumonia model, DIP was also more virulent than Newman but the effect was less pronounced. Whole genome sequencing data analysis identified a pore-forming toxin gene, lukF-PV(P83)/lukM, in DIP but not in the other tested S. aureus isolates. To conclude, the mouse-adapted S. aureus strain DIP allows a significant reduction of the inoculation dose in mice and is hence a promising tool to develop clinically more relevant infection models. KW - Staphylococcus aureus KW - host-adapted KW - infection model KW - mouse KW - vole KW - CC49 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229081 VL - 309 ER - TY - JOUR T1 - einBlick - Ausgabe 29 - 25. Juli 2017 N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Universität KW - Würzburg KW - University KW - Wuerzburg KW - Wurzburg Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-160339 UR - https://www.uni-wuerzburg.de/aktuelles/einblick/ VL - 29/2017 ER - TY - JOUR T1 - einBlick - Ausgabe 15 - 28. April 2015 N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Würzburg KW - Universität KW - Wurzburg KW - Wuerzburg KW - University Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-112404 UR - http://www.presse.uni-wuerzburg.de/einblick/ VL - 15/2015 ER - TY - JOUR T1 - einBlick - Ausgabe 34 – 26. September 2023 T2 - einBlick N2 - Nachrichten aus der Julius-Maximilians-Universität Würzburg KW - Universität KW - Würzburg KW - University KW - Wuerzburg KW - Wurzburg Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-327998 UR - https://www.uni-wuerzburg.de/aktuelles/einblick/ VL - 34/2023 ER - TY - JOUR A1 - Tony, Hans-Peter A1 - Burmester, Gerd A1 - Schulze-Koops, Hendrik A1 - Grunke, Mathias A1 - Henes, Joerg A1 - Kötter, Ina A1 - Haas, Judith A1 - Unger, Leonore A1 - Lovric, Svjetlana A1 - Haubitz, Marion A1 - Fischer-Betz, Rebecca A1 - Chehab, Gamal A1 - Rubbert-Roth, Andrea A1 - Specker, Christof A1 - Weinerth, Jutta A1 - Holle, Julia A1 - Müller-Ladner, Ulf A1 - König, Ramona A1 - Fiehn, Christoph A1 - Burgwinkel, Philip A1 - Budde, Klemens A1 - Sörensen, Helmut A1 - Meurer, Michael A1 - Aringer, Martin A1 - Kieseier, Bernd A1 - Erfurt-Berge, Cornelia A1 - Sticherling, Michael A1 - Veelken, Roland A1 - Ziemann, Ulf A1 - Strutz, Frank A1 - von Wussow, Praxis A1 - Meier, Florian MP A1 - Hunzelmann, Nico A1 - Schmidt, Enno A1 - Bergner, Raoul A1 - Schwarting, Andreas A1 - Eming, Rüdiger A1 - Schwarz-Eywill, Michael A1 - Wassenberg, Siegfried A1 - Fleck, Martin A1 - Metzler, Claudia A1 - Zettl, Uwe A1 - Westphal, Jens A1 - Heitmann, Stefan A1 - Herzog, Anna L. A1 - Wiendl, Heinz A1 - Jakob, Waltraud A1 - Schmidt, Elvira A1 - Freivogel, Klaus A1 - Dörner, Thomas A1 - Hertl, Michael A1 - Stadler, Rudolf T1 - Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) JF - Arthritis Research & Therapy N2 - Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm) KW - GRAID Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142856 VL - 13 IS - R75 ER -